- Home
- AUST vs INAB Comparison
AUST vs INAB Comparison
Compare AUST & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AUST | INAB |
|---|---|---|
| Founded | 2020 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2M | 22.9M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AUST | INAB |
|---|---|---|
| Price | $2.20 | $2.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $108.00 |
| AVG Volume (30 Days) | ★ 2.9M | 144.5K |
| Earning Date | 02-26-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.05 | $1.17 |
| 52 Week High | $3.92 | $12.53 |
Technical Indicators
Market Signals| Indicator | AUST | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 67.30 | 46.60 |
| Support Level | $1.71 | $2.30 |
| Resistance Level | $3.92 | $2.73 |
| Average True Range (ATR) | 0.34 | 0.25 |
| MACD | 0.06 | -0.04 |
| Stochastic Oscillator | 26.60 | 5.69 |
Price Performance
Historical ComparisonAbout AUST Austin Gold Corp.
Austin Gold Corp is focused on the acquisition, exploration and evaluation of mineral resource properties in the western United States of America (USA). Exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek in Humboldt County, Lone Mountain and Miller in Elko County, and Stockade Mountain (Oregon).
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.